For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Gonadorelin
Illustration for Gonadorelin

THE PEPSRADAR ENCYCLOPEDIA

Gonadorelin

Hypothalamic amenorrhea and fertility physiology

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Gonadorelin · KEY FACTS

Content updated · how dates work

Saved peptides

What is Gonadorelin?

Gonadorelin is gonadotropin-releasing hormone. A clinical series studied pulsatile administration in women with hypothalamic amenorrhea, a specific reproductive-hormone disorder.

Biological role or research focus

Hypothalamic amenorrhea and fertility physiology.

These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.

Role reference: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. · 1990 ↗

Names you may encounter

GnRH-I

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Gonadotropin-releasing hormone decapeptide
Research focus
Hypothalamic amenorrhea and fertility physiology
Featured evidence
Human clinical series
Source check
October 4, 2026

Source: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. · 1990 ↗

Quick answers

Is Gonadorelin FDA approved?
It was approved but is no longer marketed. Factrel (NDA 018123, approved 1982, diagnostic) and Lutrepulse (NDA 019687) are both listed in Drugs@FDA as discontinued; no gonadorelin product is currently marketed in the US. Source ↗
Is Gonadorelin safe?
Gonadorelin was once FDA-approved (Factrel, Lutrepulse) but no human product is marketed in the US now; no current label exists, and safety data come from older studies and case reports. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
Is Gonadorelin banned in sport?
Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.1 Testosterone-stimulating peptides in males). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
Multicenter pulsatile GnRH clinical series (1990)Human clinical series109 women with primary or secondary hypothalamic amenorrhea.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human clinical series · 1990

Multicenter pulsatile GnRH clinical series

What outcomes were reported with pulsatile GnRH in hypothalamic amenorrhea?

Population / model
109 women with primary or secondary hypothalamic amenorrhea.
Study design
Multicenter clinical series of pulsatile GnRH treatment; the abstract does not describe a randomized placebo-controlled comparison.
Main finding
Reported ovulation rates were 91% in primary and 96% in secondary amenorrhea. Multiple pregnancies occurred in 12%; intravenous-line complications averaged 7%.
Limits & context
These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.

Source: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. · 1990 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming Gonadorelin as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Premenstrual syndrome. ↗
BMJ clinical evidence · 2007 May 1 · Journal Article, Systematic Review

Breast pain. ↗
BMJ clinical evidence · 2011 Jan 17 · Journal Article, Systematic Review
Read available full text ↗

Endometriosis. ↗
BMJ clinical evidence · 2007 Mar 1 · Journal Article, Systematic Review
Read available full text ↗

Endometriosis. ↗
BMJ clinical evidence · 2010 Aug 13 · Journal Article, Systematic Review
Read available full text ↗

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Gonadorelin was once FDA-approved (Factrel, Lutrepulse) but no human product is marketed in the US now; no current label exists, and safety data come from older studies and case reports.

Human safety data: Very limited

We found no archived FDA label; Drugs@FDA lists Factrel and Lutrepulse as discontinued. Evidence comes from older clinical series, such as a 1990 trial in 109 women, and case reports. Modern, controlled safety data are lacking.

No condition tags: its FDA label does not single out these conditions. If a condition applies to you, talk to a doctor or pharmacist first.

Serious risks

  • Multiple pregnancy when used to trigger ovulation (about one in eight in one trial)
  • Complications from the intravenous line used to give it
  • Severe allergic reactions, including anaphylaxis, in rare case reports

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Drugs@FDA: Factrel, NDA 018123 (discontinued) ↗ · Drugs@FDA: Lutrepulse, NDA 019687 (discontinued) ↗ · Santoro, Am J Obstet Gynecol 1990: efficacy and safety of Lutrepulse ↗ · Akin et al., J Pediatr Endocrinol Metab 2015: anaphylaxis to gonadorelin acetate ↗ · Foster et al., Am J Obstet Gynecol 1989: IgE hypersensitivity to gonadorelin (Factrel) ↗

What the featured evidence can tell us

Multiple pregnancy and intravenous-line complications were reported. The study cannot establish safety or benefit for unrelated reproductive disorders.

Source: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. · 1990 ↗

Identity, route, and evidence limits

These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.

Source: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. · 1990 ↗

Regulatory status

U.S. FDA approval
Approved, now discontinued
Factrel (NDA 018123, approved 1982, diagnostic) and Lutrepulse (NDA 019687) are both listed in Drugs@FDA as discontinued; no gonadorelin product is currently marketed in the US. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Prohibited, named on the list · S2.2.1 Testosterone-stimulating peptides in males
Named explicitly ("gonadotrophin-releasing hormone (GnRH, gonadorelin)"); prohibited in males. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical context & research status

The selected report concerns specialist fertility treatment in hypothalamic amenorrhea. It does not establish general testosterone enhancement or fertility improvement across all causes.

Source: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. · 1990 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

How Gonadorelin works

The timing of GnRH signaling matters. Pulsatile replacement and sustained stimulation by a long-acting analogue can produce different endocrine effects; the names cannot be treated as interchangeable interventions.

Source: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. · 1990 ↗

Molecular structure

Gonadorelin: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 638793 ↗

Questions worth asking

  • Is pulsatile gonadorelin equivalent to a long-acting GnRH agonist?
  • What population, comparator, and route were actually studied?
  • These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Is pulsatile gonadorelin equivalent to a long-acting GnRH agonist?

No. Pulsatile signaling can stimulate reproductive hormone release, whereas sustained agonist exposure may suppress the pathway. Clinical purpose and timing matter.

Source: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. · 1990 ↗

Does this page establish a supplier’s product quality?

No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.

Source: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. · 1990 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Gonadorelin

Download illustration ↓Source record ↗
Gonadorelin 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.